Kantonsspital St.Gallen

Peter J Wild

Kontakt

Peter J Wild

Publikationen (9)

Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Jörger M, Alonso G, Goebeler M, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz M, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo J, Koster K, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt A, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle P, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll F, Wild P, Chun F, Reis H, Lloyd P, Machacek M, Gajewski T, Fridman W, Eggermont A, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, Dantas-Silva A, Lichtenegger F, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2024

Britschgi C, Banna G, Wild P, Rothschild S, Gautschi O, Banini M, Metro G, Früh M, Delaloye R, Rechsteiner M, Addeo A, Curioni-Fontecedro A. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol 2020; 10:1299.

Zhu Y, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P, Aebersold R, Ljubicic J, Rutishauser D, Schmid M, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol Oncol 2019; 13:2305-2328.

Guo T, Aebersold R, Wild P, Poyet C, Saba K, Fankhauser C, Jochum W, Rueschoff J, Wagner U, Wong C, Charmpi K, Rupp N, Zhong Q, Li L, Beyer A. Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Sci Alliance 2018; 1

Zhong Q, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Rogel U, Vassella E, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey J, Wild P. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. Pathol Res Pract 2018; 214:957-963.

Fankhauser C, Moch H, Sulser T, Poyet C, Hermanns T, Rueschoff J, Rupp N, Omlin A, Gillessen Sommer S, Schüffler P, Wild P. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2017; 9:10284-10293.

Zhong Q, Poyet C, Blattner M, Soldini D, Moch H, Rubin M, Noske A, Rüschoff J, Haffner M, Jochum W, Perner S, Buhmann J, Rüschoff J, Guo T, Gabrani M, Schüffler P, Rechsteiner M, Liu Y, Fuchs T, Rupp N, Fankhauser C, Wild P. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci Rep 2016; 6:24146.

Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.

Riener M, Moch H, Clavien P, Hellerbrand C, Jungbluth A, Jin B, Knuth A, Soll C, Wild P, Jochum W. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. International journal of cancer. Journal international du cancer 2009; 124:352-7.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen Rorschacher Strasse 95 CH-9007 St.Gallen T: +41 71 494 11 11 support.forschung@kssg.ch